ASP Isotopes Inc. · NASDAQ:ASPI
ASP Isotopes — Investor Presentation (June 2023)
30 slides from ASP Isotopes's investor presentation, June 2023
Slide 1: Corporate Overview
Corporate Overview June 2023 © ASP Isotopes Inc. 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements”. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, fu
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will ASP Isotopes (NASDAQ: ASPI) enable the company to manufacture a diverse range of isot
Slide 4: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights 1. Cost-Effective Isotope enrichment facilities using ASP technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. This technology has been refined for over 20 years through the South African Nuclear Enric
Slide 5: ASP Isotopes: Macro Highlights
ASP Isotopes: Macro Highlights 1. Geopolitical Tailwinds Recent geopolitical events have made governments and companies worldwide reassess their reliance on Russia to produce isotopes. Russia’s production share of the global medical isotope market is 22%, and China and Russia together comprised 57%
Slide 6: Company History
Company History October 2021 • ASP Isotopes wins competitive auction for July 2022 March 2023 December 2020 Klydon Large-scale Plant Acquisition of the Small-Scale Introduction to Klydon • Raised an additional $6 million and ASP announces the commissioning Plant enrichment facility from commenced pr
Slide 7: Anticipated Milestones
Anticipated Milestones MARKET MILESTONES OPERATIONAL MILESTONES 1. Secure at least 2 more supply agreements for 1. Complete the construction and commissioning of our isotopes critical for new technologies and larger isotope enrichment facility in South Africa – healthcare. 2H23 2. Generate sufficien
Slide 8: ASP Isotopes Leadership Team
ASP Isotopes Leadership Team PAUL MANN SERGEY VASNETSOV HENDRIK STRYDOM, PhD Chairman, and CEO Vice-Chairman of the Board Director, Chief Technology Officer ▪ Co-founded ASP Isotopes in ▪ Founder and Managing Director ▪ Co-developer of “Aerodynamic September 2021 of ChemBridges, strategy Separation
Slide 9: What Is An Isotope?
What Is An Isotope? Molybdenum (Mo) has 7 stable isotopes, where Molybdenum-100 content in the natural mix is only 10%. Isotopes are like identical twins or triplets: very similar in most aspects, except for a few subtle differences. • Isotopes are two or more atoms of the same chemical element with
Slide 10: Isotopes of Interest
Isotopes of Interest Under Commercially Isotopes End-Market R&D Stage R&D Evaluation Construction Available Carbon-14 Pharma & Agrochem Silicon-28 Quantum Computing Germanium-70/72/74 Quantum Computing Available in Molybdenum-100 2H23 Nuclear Medicine Available in Molybdenum-98 2H23 Zinc- 67/68 Ytte
Slide 11: ASP Technology Creates Stable Isotopes More Efficiently
ASP Technology Creates Stable Isotopes More Efficiently TRADITIONAL TECHNOLOGY ASP DIFFERENTIATION TRADITIONAL TECHNOLOGY Expensive and Capital intensive Cost-effective proprietary design Enables long-term value capture Traditionally, isotopes have been ▪ In separation, the cylinder wall remains ▪ A
Slide 12: ASP Technology: Stationary Wall Centrifuge
ASP Technology: Stationary Wall Centrifuge Benefits of a Stationary Wall Centrifuge V 1. No moving parts vs. a conventional centrifuge 2. No unique materials are required 3. Cost-efficient at small scale 4. High Separation Efficiency Small Production Flexible Capacity Modules Deployment High Separat
Slide 13: Isotope End Markets: Nuclear Medicine
Isotope End Markets: Nuclear Medicine ISOTOPES OF INTEREST 14C 99Tc 68Ga 67Cu 67Cu 177Lu END MARKET Carbon-Dating PET Scan imaging Oncology Oncology SPECT Scan Treatment Treatment Pharmacokinetic Imaging Oncology (Non-Hodgkin (Neuroendocrine Tracing Treatment lymphoma, Prostate Tumors NETs) Cancer,
Slide 14: Isotope End Markets: Carbon-14
Isotope End Markets: Carbon-14 (14C) A scientific technique used to track the passage of a Radiolabeling molecule. The technique incorporates a radioisotope ASPI’s Carbon-14 enrichment facility through a reaction, cell, organism, biological system, or metabolic pathway. Used as a radiolabeling compo
Slide 15: Isotope End Markets: Molybdenum-100 and Zinc-68
Isotope End Markets: Molybdenum-100 and Zinc-68 Imaging Agent Distribution Single-photon emission 99Tc computed tomography (SPECT) It is estimated that 80-85% of all Technetium-99 SPECT procedures utilize Global Market Size6 Technetium-998 99Tc Global Market Size7 $4.61B $4.17B Imaging Agent Distrib
Slide 16: Nuclear Medicine Supply Chain
Nuclear Medicine Supply Chain Current Mo99 Supply Chain Current Isotope Conversion Process ASP Isotope Conversion Process 99Mo 99Tc 100Mo 99Tc Half-Life: 66 Hours Half-Life: 6 Hours STABLE Half-Life: 6 Hours © ASP Isotopes Inc. 16
Slide 17: Geopolitical Tailwinds for ASPI Nuclear Medicine
Geopolitical Tailwinds for ASPI Nuclear Medicine World’s Largest Nuclear Facilities Manufacturing Isotopes 1. Government Support for Alternative Supply “Between 95 and 98 percent of 99Mo is currently being produced using highly enriched uranium (HEU) targets, which was the major concern of Congress.
Slide 18: Isotopes End-Markets: Green Nuclear Energy
Isotopes End-Markets: Green Nuclear Energy Nuclear Power provides ~10% of global electricity generation13 NUCLEAR FUEL SOURCES HIGH ASSAY LOW ENRICHED URANIUM LOW-ENRICHED URANIUM HALEU (15-19.75%) LEU (5%) To reach Net Zero emissions by 2050, the World Must: In 2021 nuclear power capacity declined
Slide 19: Leveraging ASP Technology in Green Nuclear Energy
Leveraging ASP Technology in Green Nuclear Energy OUR SOLUTION 1. Enrich LEU (5.0%) + HALEU (15-19.75%) Our Process produces waste with Uranium-235 content at 0.71%. Equivalent to naturally occurring uranium NEXT STEPS Demonstrate the effectiveness of ASP for 2. Conduct Bench Tests 235U enrichment F
Slide 20: Geopolitical Tailwinds for ASPI Green Nuclear Energy
Geopolitical Tailwinds for ASPI Green Nuclear Energy Energy Security Increasing Focus on Nuclear Power By Country ▪ Russia is responsible for 35% of ▪ UK plans to build 8 new nuclear power plants to increase enriched uranium globally15 nuclear power from 15% to 25% of the mix by 2050.10 ▪ The United
Slide 21: Market Opportunities of Other Isotopes
Market Opportunities of Other Isotopes For Use in Quantum Computing For Use in Oncology 1. Quantum computing requires ultra-pure Silicon-28 1. Ytterbium-176 is emerging as a better method of Which is not available at any price at commercial producing Lutetium-177, which is an emerging scale therapeu
Slide 22: Investment Thesis
Investment Thesis 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will meet the growing de
Slide 23: Supplemental Background Information
Supplemental Background Information © ASP Isotopes Inc. 23
Slide 24: Isotope Enrichment Map
Isotope Enrichment Map 176Yb and 138Xe = 14C = Commercially Available active consideration 28Si = Available post plant completion 100Mo and 98Mo = plant in final stages of 64Ni and 68Zn = active construction consideration 235U, 6Li and 37Cl = © ASP Isotopes Inc. Green Energy 24
Slide 25: Advantages of ASP vs. Competing Technologies
Advantages of ASP vs. Competing Technologies Energy Used for Energy Process Separation Mechanism Capex Cost Separation Intensity, kWh ▪ ASPI has a robust, versatile platform of Differential Diffusion isotope enrichment technologies – Diffusion through porous Mechanical 2,500 High which can offer sol
Slide 26: Technetium-99m Production Pathways
Tcechnetium-99m Production Pathways ▪ 99Tc can be produced using 100Mo or ▪ 100Mo and 98Mo are stable and do not undergo radioactive decay; they can 98Mo either directly or indirectly therefore be shipped and stored like traditional products, removing many supply chain issues associated with the cur
Slide 27: Silicon-28: Enabling Quantum Computing
Silicon-28: Enabling Quantum Computing Quantum Computers are expected to be 1000x more powerful than today’s conventional computers, and widely anticipated that they will create new opportunities in medicine, artificial intelligence, cybersecurity, finance, logistics, and other industries. For the p
Slide 28: SMR (Small Modular Reactors) = Next Wave in Nuclear Energy
SMR (Small Modular Reactors) = Next Wave in Nuclear Energy TerraPower’s Natrium The world is moving to a new type of nuclear reactor: SMR ▪ Modular, smaller size (50 MWe to 300 MWe) reactors allowing greater flexibility in deployment ▪ Designed for production-line manufacturing rather than conventio
Slide 29: HALEU Supply Issue Looming for SMR Reality
Annual US Demand Growth for HALEU 700 600 HALEU Supply Issue 500 Looming for SMR Reality 400 300 ▪ Current commercial LWRs use low-enriched uranium 200 (LEU) which has less than 5% 235U content. 100 ▪ Many SMRs and advanced reactors will require High 0 Assay Low Enriched Uranium (HALEU) with 235U 20
Slide 30: Data Sources
Data Sources 1. Wang, Yiwei et al. “Production Review of Accelerator-Based Medical Isotopes.” Molecules (Basel, Switzerland) vol. 27,16 5294. 19 Aug. 2022, doi:10.3390/molecules27165294. 2. B.L. Zhukov et al. "Production of medical radionuclides in Russia: Status and future - a review.” Applied Radi